As expected, U87MG glioma cells expressing the IDH1-R132H mutant and patient-derived xenografts from IDH1 mutant GBM both showed lower cellular NADPH levels and a decreased [NADPH]/[NADP+] ratio [102,103]. This evidence concerns the gene IDH1 and central nervous system cancer.